# Bofanglutide — dosage, half-life & reference guide

Source: https://pepvault.app/peptides/bofanglutide

Last updated: 2026-11-19

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Metabolic & GLP-1](https://pepvault.app/peptides#metabolic)

# Bofanglutide Dosage, half-life & reference guide

Also known as GZR18 · Bofa

Reviewed November 2026 Evidence: Moderate [Published by PepVault](https://pepvault.app/guides/how-we-research)

A GLP-1 drug from Gan & Lee Pharmaceuticals designed for one shot every two weeks, with a long fatty-acid chain that makes it act gently and last. In its 52-week phase 3 trial in China, people lost about 15% (24 mg) and 18.5% (48 mg) of their weight, and a follow-on trial found that one shot a month then held the loss.

- **Studied range:** 12–48 mg starting dose 3 mg
- **How often:** Every 2 weeks
- **Half-life:** ~7 days
- **Evidence:** Moderate
- **Route:** SubQ injection

Studied in research — not a recommendation.

[Bofanglutide dose guide](https://pepvault.app/lab/dosage/bofanglutide)

## How it works.

GLP-1 receptor agonist, semaglutide's receptor, built from human GLP-1 with no unnatural amino acids and a long 22-carbon fatty-acid chain. The chain binds it tightly to albumin and slows its release from under the skin, so activity is gentler and longer: its half-life in people is about 7 days, and its trials give it once every two weeks. Developed by Gan & Lee Pharmaceuticals in China, in phase 3 there and phase 2 in the US.

**Commonly reported:** GI side effects during the step-ups, as with other GLP-1 drugs. It is not approved anywhere yet.

### Half-life & active level

The half-life of Bofanglutide is ~7 days (measured in people: phase 1 in American and Chinese adults, Liu 2025).

Here's how a typical Bofanglutide schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in [the half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator).

Your report

## Taken Bofanglutide? What did you notice?

One tap to start. About 30 seconds, no account.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track bofanglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Where Bofanglutide works.

- ### Appetite & metabolism

  **In people.** A GLP-1 drug from Gan & Lee Pharmaceuticals designed for one shot every two weeks, with a long fatty-acid chain that makes it act gently and last.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

## Week by week.

What to expect in the first 8 weeks

- **Onset:** Days–2 weeks
- **Peak effect:** 52 weeks (phase 3 endpoint)
- **Duration:** Ongoing

1. Day 1–28 · 3 mg RCT

   ### Three milligrams, the first step

   You're on 3 mg, where every group in the phase 2b trial began. Commonly reported: appetite dropping within days. In that trial, GI side effects came mostly in the early step-ups and eased over time.

   The science

   Phase 2b (Ji 2026; 340 Chinese adults): all groups started at 3 mg and escalated every 2–4 weeks (12 mg: 3-6-9-12; 24 mg: 3-6-9-12-18-24; 48 mg: 3-6-12-24-36-48). GI AEs "occurred predominantly during the early dose-escalation period and gradually decreased over time"; the 48 mg group, without the 9 and 18 mg steps, had the most, and the intermediate steps "substantially reduced the incidence of gastrointestinal AEs".

   Sources

   - Ji et al. (phase 2b) (2026)

   Updated Nov 2026
2. Day 29–210 · 12 mg RCT

   ### Twelve milligrams every two weeks

   You're at 12 mg, the lowest maintenance dose in the phase 2b trial. Given every two weeks, it took off about 10% of body weight by week 30, against about 1% on placebo.

   The science

   Phase 2b, week 30: 12 mg every 2 weeks −9.75% vs −1.15% on placebo (difference −8.60%); 18 mg −12.55% (difference −11.39%) (Ji 2026). Nausea 34.6% and vomiting 25.0% at 12 mg vs 9.1% and 12.1% on placebo.

   Sources

   - Ji et al. (phase 2b) (2026)

   Updated Nov 2026
3. Any day RCT

   ### What Bofanglutide is built on

   Phase 1 trials in the US and China, a phase 1b/2a and a 30-week phase 2b in obesity, two phase 3 trials in China, and a US phase 2 against tirzepatide. It is not approved anywhere yet.

   The science

   Phase 1 (Liu 2025, Diabetes Obes Metab): half-life about 7 days in both American and Chinese adults, Tmax 60-96 h. Phase 1b/2a (Ji 2026, Cell Rep Med). Phase 2b (Ji 2026, Signal Transduct Target Ther; NCT06256562, sponsor Gan and Lee Pharmaceuticals). Phase 3: GRADUAL-1 (NCT06728124), GRADUAL-3, and a trial against semaglutide (Wegovy) (NCT07150975), plus sleep apnea trials; type 2 diabetes phase 3 (NCT06777238) completed.

   Sources

   - Liu et al. (2025)
   - Ji et al. (phase 1b/2a) (2026)
   - Ji et al. (phase 2b) (2026)

   Updated Nov 2026
4. With BPC-157 Community

   ### Why people add BPC-157 to a GLP-1

   GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.

   The science

   BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside bofanglutide or any GLP-1 drug; the pairing comes from community reports.

   Sources

   - Sikiric et al. (2018)

   Updated Nov 2026

### After week 8

1. Day 57–364 · 24 mg RCT

   ### Twenty-four milligrams, a phase 3 dose

   You're at 24 mg, one of the two doses in the phase 3 trial. Every two weeks, it took off about 15% of body weight at 52 weeks, and more than 9 in 10 lost at least 5%.

   The science

   GRADUAL-1 (NCT06728124; 640 Chinese adults, baseline 93.7 kg): 24 mg every 2 weeks −15.12% vs −1.11% on placebo at week 52; 91.8% reached ≥5% (Gan & Lee, Jun-12-2026; topline). Phase 2b: 24 mg every 2 weeks −13.66% and 24 mg weekly −16.69% at week 30 (Ji 2026).

   Sources

   - Gan & Lee (GRADUAL-1 release) (2026)
   - Ji et al. (phase 2b) (2026)

   Updated Nov 2026
2. Day 85–364 · 48 mg RCT

   ### The top dose

   You're at 48 mg, the highest dose tested. In the phase 3 trial it took off about 18.5% at 52 weeks. GI side effects were more common at this dose, especially with big steps on the way up.

   The science

   GRADUAL-1: 48 mg every 2 weeks −18.54% vs −1.11% at week 52; 98.1% reached ≥5% (Gan & Lee, Jun-12-2026). Phase 2b at 48 mg: −16.09% at week 30; nausea 64.1%, vomiting 62.5%, diarrhea 37.5%; completion 72% vs 85-92% in other groups (Ji 2026). US phase 2 (NCT06737042, 326 people): 48 mg −15.18% at 36 weeks with no plateau vs −16.93% on open-label tirzepatide 15 mg (Gan & Lee, Jun-12-2026).

   Sources

   - Gan & Lee (GRADUAL-1 release) (2026)
   - Ji et al. (phase 2b) (2026)

   Updated Nov 2026
3. Day 365+ RCT

   ### One shot a month to hold it

   After a year of shots every two weeks, Gan & Lee tested one shot a month. Over the next 24 weeks, weight held steady on the monthly dose, while those switched to placebo regained about 8.5%. Whether to continue, space out or stop is a call for you and your clinician.

   The science

   GRADUAL-3 (phase 3b): participants who completed 52 weeks of GRADUAL-1 were randomised by their last dose to bofanglutide 24 or 48 mg or placebo once monthly for 24 weeks: weight change +0.41% and −0.12% vs +8.52% on placebo (both p < 0.0001); mostly mild to moderate, transient GI events, no new safety signals (Gan & Lee, Nov-4-2026; topline).

   Sources

   - Gan & Lee (GRADUAL-3 release) (2026)

   Updated Nov 2026

Day 1 is the day you start it.

Phase 1 (Liu 2025, Diabetes Obes Metab), phase 2b (Ji 2026, Signal Transduct Target Ther; NCT06256562), Gan & Lee releases Jun-12-2026 (GRADUAL-1, US phase 2) and Nov-4-2026 (GRADUAL-3), registry records. Investigational.

Moderate evidence

## More on bofanglutide

### Dose Guide

- [Bofanglutide dose guide](https://pepvault.app/lab/dosage/bofanglutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bofanglutide-10mg)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)

## Mixing and a typical run.

Example numbers

### Reconstitution example

Reconstitute a 10 mg vial of Bofanglutide with 2 mL of bacteriostatic water and a 3 mg dose is 60 units on a U-100 syringe, about 3 doses per vial.

- **Vial:** 10 mg
- **Water:** 2 mL
- **Amount:** 3 mg

Draw to **60 units**

1 mL insulin syringe · 100 units

[Mix it in the Reconstitution Lab](https://pepvault.app/lab) [Open the calculator](https://pepvault.app/tools/reconstitution-calculator)

### Run notes

- **Cycle:** Used continuously in its trials: every 2 weeks for 30 to 52 weeks, with steps every 2 to 4 weeks. In the GRADUAL-3 maintenance trial, people who had finished 52 weeks moved to one shot a month and held their weight for 24 weeks, while those switched to placebo regained about 8.5%. Community practice — opinions vary. Not a clinical recommendation.
- **Timing:** One SubQ shot every 2 weeks in its main trials (weekly in one phase 2b arm), from a GanleePen. The phase 2b started every group at 3 mg and stepped up every 2 to 4 weeks, through 6, 9, 12 and 18 mg to 24 mg, or in bigger jumps to 48 mg. After a year, one shot a month was tested to hold the loss. These are trial schedules, not an approved regimen.
- **Route:** SubQ injection
- **Stacks:** BPC-157 (GI support)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-next-mixing&mt=8)

<!--/promo-->

## Safety.

### Common side effects

- Nausea
- Vomiting
- Diarrhea
- Decreased appetite

#### Interactions

No interaction results have been published; Gan & Lee has run studies of its effect on stomach emptying and on other drugs (NCT07128888) and on metformin (NCT06670209). GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

### Safety notes

Bofanglutide has no label: it is still in trials. In the 30-week phase 2b trial, GI side effects (nausea, vomiting, diarrhea) affected 79% to 91% on bofanglutide vs 33% on placebo, mostly grade 1 to 2 and early in the step-ups; they were highest in the 48 mg group, which took bigger dose jumps, and adding in-between steps lowered them. In phase 3 the safety profile matched other GLP-1 drugs, with mostly mild to moderate, transient GI events and no new safety signals. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

## Goes with.

- [BPC-157 GI support](https://pepvault.app/peptides/bpc-157)

## One question at a time.

- [Half-life](https://pepvault.app/peptides/bofanglutide/half-life)
- [Side effects](https://pepvault.app/peptides/bofanglutide/side-effects)
- [How long it takes to work](https://pepvault.app/peptides/bofanglutide/how-long-to-work)

## Mixing charts by vial size.

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bofanglutide-10mg)

## Questions people ask.

### What is Bofanglutide?

A GLP-1 drug from Gan & Lee Pharmaceuticals designed for one shot every two weeks, with a long fatty-acid chain that makes it act gently and last. In its 52-week phase 3 trial in China, people lost about 15% (24 mg) and 18.5% (48 mg) of their weight, and a follow-on trial found that one shot a month then held the loss.

### How is Bofanglutide dosed in research?

The research range for Bofanglutide is 12–48 mg, every 2 weeks (or weekly), with a 3 mg starting dose. Studied in research — not a recommendation.

### How long does Bofanglutide last?

The half-life of Bofanglutide is ~7 days (measured in people: phase 1 in American and Chinese adults, Liu 2025).

### What do people report on Bofanglutide?

Commonly reported on Bofanglutide: GI side effects during the step-ups, as with other GLP-1 drugs. It is not approved anywhere yet.

### Is Bofanglutide safe?

The research basis for Bofanglutide is moderate: animal studies + some human data. Common side effects in the library: nausea, vomiting, diarrhea and decreased appetite.

### What does Bofanglutide stack with?

Common stacks for Bofanglutide: BPC-157 (GI support).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-next-questions&mt=8)

<!--/promo-->

## Research.

The literature

### Search the latest research

[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Bofanglutide) [Google Scholar](https://scholar.google.com/scholar?q=Bofanglutide)

## Reference.

- **Cadence:** Every 2 weeks Every 2 weeks (or weekly)
- **Half-life:** ~7 days ~7 days (measured in people: phase 1 in American and Chinese adults, Liu 2025)
- **Research basis:** Moderate Animal studies + some human data

## More metabolic & glp-1 peptides

- [Efinopegdutide 4–10 mg](https://pepvault.app/peptides/efinopegdutide)
- [5-Amino-1MQ 50–100 mg](https://pepvault.app/peptides/5-amino-1mq)
- [SLU-PP-332 250–1000 mcg](https://pepvault.app/peptides/slu-pp-332)
- [L-Carnitine (injectable) 700–1400 mg](https://pepvault.app/peptides/l-carnitine-injectable)
- [Tesofensine 0.25–0.5 mg](https://pepvault.app/peptides/tesofensine)
- [Oxytocin 10–40 IU](https://pepvault.app/peptides/oxytocin)

## Free tools

- [Bofanglutide dose guide](https://pepvault.app/lab/dosage/bofanglutide)
- [Reconstitution Lab (3D)](https://pepvault.app/lab)
- [Injection guide (3D)](https://pepvault.app/lab/injection)
- [Peptide Sky (3D)](https://pepvault.app/lab/sky)
- [Peptide tier list](https://pepvault.app/lab/tiers)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

<!--promo-->

PepVault for iPhone

## Track bofanglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track bofanglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## More on bofanglutide

### Dose Guide

- [Bofanglutide dose guide](https://pepvault.app/lab/dosage/bofanglutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bofanglutide-10mg)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)

<!--promo-->

PepVault for iPhone

## Track bofanglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library)

<!--promo-->

Track your progress

## Watch it *work.*

Weight, waist and photos in one arc.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=peptides-progress-band&mt=8)

**34.8 lbs** down since June

Model. Individual results vary.

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
